Skip to main content
OpenTrials
Completed

NCT Number: NCT02785991

Spanish Registry of Cryoballoon Ablation

The purpose of this registry is to reflect on standard clinical practice in pulmonary vein cryoablation in Spanish hospitals, the different procedure protocols, details of intervention, complications, long-term follow-up strategy and results in these subjects.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospital Trias i Pujol, Badalona, Barcelona, Spain

Loading trial locations.

About this study

With this study the investigators propose the performance of a prospective registry of pulmonary vein cryoablation in subjects with paroxysmal or persistent AF at Spanish sites to estimate evaluate the efficacy of the cryoablation procedure at 12 months, defined as the absence of recurrences of atrial fibrillation.

Secondary objectives are also defined as:

  • Description of the profile of subjects who undergo this type of procedure (demographic factors, cardiovascular risk factors, medication, physical activity, sleep apnea, alcohol, smoking, chronic pulmonary disease, obesity, etc.).
  • To evaluate the acute efficacy of the procedure: complete isolation of the pulmonary veins demonstrated by the successful electrical disconnection of the pulmonary veins in the cryoablation procedure.
  • Description of the complications related to the procedure.
  • To evaluate the use of healthcare resources which this cryoablation procedure entails.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signature of the Data Release Form
  • Subjects ≥ 18 years old
  • Subjects who meet the indication for the Cryoballoon Ablation procedure.

Exclusion criteria

  • Subjects with a life expectancy of less than 12 months.
  • Subjects who meet the exclusion criteria defined by local legislation (e.g., age, pregnancy, breastfeeding, etc.).
  • Subjects who may currently be enrolled, or who plan to take part, in a study with a drug or device that may cause bias during the course of this study.
  • Co-participation in concurrent trials is only allowed when documented pre-approval is obtained from the Medtronic study manager.

Treatment and study plan

Balloon cryoablation

Procedure

pulmonary vein cryoablation for atrial fibrillation

Primary outcomes

  1. The Efficacy of the Cryoablation Procedure at 12 Months, Defined as the Absence of Recurrences of Atrial Fibrillation.

    Time frame: 12 months

    Percentage of patients freedom from Recurrences of Atrial Fibrillation at 12 months (on ECG, Holter monitor with a duration of at least 30 seconds or implantable devices or event recording systems).

Secondary outcomes

  1. The Acute Efficacy of the Procedure:

    Time frame: 24-48h

    Complete isolation of the pulmonary veins demonstrated by the successful electrical disconnection of the pulmonary veins in the cryoablation procedure.

  2. Number of Adverse Events Related to the Procedure

    Time frame: Up 30 days post procedure

    The outcome measure is the number of Adverse Events Related to the Procedure

Sponsors and collaborators

Lead sponsor

Medtronic Cardiac Ablation Solutions

Industry

Collaborators

  • Medtronic

Registry information

Official study title

Prospective Observational Study of Pulmonary Vein Cryoablation in Subjects With Atrial Fibrillation (AF) in Spain

Acronym: RECABA

Important dates

Study start
2016
Primary completion
2020
Study completion
2021
First posted
May 30, 2016
Registry last updated
Mar 14, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.